Meibomian Gland Dysfunction in Type 2 Diabetic Patients

Area of Science:

• Ophthalmology
• Endocrinology
• Ocular Surface Disease

Background:

• Type 2 diabetes is a systemic condition affecting multiple organs.
• Ocular complications of diabetes are well-documented, but meibomian gland and tear film function are less studied.

Purpose of the Study:

• To investigate meibomian gland and tear film function in patients with type 2 diabetes.
• To compare ocular surface parameters in type 2 diabetic patients versus non-diabetic controls.

Main Methods:

• Prospective study comparing type 2 diabetic patients and non-diabetic individuals.
• Meibomian gland evaluation included lipid layer thickness, meibomian gland loss, lid margin abnormalities, and meibum expression.
• Tear film assessment involved tear breakup time (TBUT), Schirmer I test, noninvasive breakup time (NIBUT), tear meniscus height (TMH), and corneal staining.

Main Results:

• Diabetic patients had significantly higher meibography scores, indicating more severe meibomian gland loss.
• Fewer expressible meibomian glands were observed in all thirds of the lower eyelid in the diabetic group.
• Higher lid margin abnormality scores were found in diabetic patients, but tear film function parameters showed no significant differences between groups.

Conclusions:

• Meibomian gland dysfunction (MGD) is more severe in type 2 diabetic patients compared to non-diabetics.
• A significant proportion of type 2 diabetic patients present with asymptomatic MGD.
• These findings highlight the ocular surface impact of diabetes, particularly on the meibomian glands.